Clinical Research & Innovation in Beverly Hills, CA

Redefining the Frontiers of Rheumatology and Patient Quality of Life
GLOBAL IMPACT AND LEADERSHIP

A Legacy of Academic and Clinical Authority

Dr. Stuart Silverman
Dr. Stuart L. Silverman is not just a clinician, he is a Key Opinion Leader (KOL) whose research has fundamentally shaped how the global medical community understands and treats chronic illness. With a career spanning over four decades, he has published more than 300 original articles, book chapters, and editorials.

The impact of his work is quantified by a citations count of over 13,326 and an H-index of 55. To put this in perspective, an H-index above 35 is often associated with Nobel Prize winners, placing Dr. Silverman in the top 5% of physicians worldwide for research impact.
Beverly Hills, California, USA rooftop skyline view with focus on palm trees
THE OMC CLINICAL RESEARCH CENTER

Bringing Tomorrow’s Medicine to Beverly Hills Today

As the Medical Director of the OMC Clinical Research Center, Dr. Silverman leads a nonprofit public benefit corporation dedicated to clinical discovery. The OMC serves as a bridge between major academic medical centers and the community, conducting trials that explore the next generation of treatments for Osteoporosis, Fibromyalgia, and Osteoarthritis.

Supported by federal (NIH) and state funding, as well as pharmaceutical partnerships, the OMC has been at the forefront of FDA-approved medication trials for over 20 years.
Close up of Sport man suffering with pain on sports running knee injury after running
REVOLUTIONIZING BONE HEALTH

Pioneering Research in Osteoporosis

Dr. Silverman’s work in bone health focuses on making complex data understandable and actionable for patients. He recognizes that bone strength is a combination of both quantity (DEXA) and quality (TBS).
 
  • The OPAQ Instrument: Dr. Silverman developed the first quality of life instrument for osteoporosis patients, known as the Osteoporosis Assessment Questionnaire (OPAQ).
 
  • The FRAX Color-Code Study: He is currently working to change how fracture risk is communicated. By moving from numerical FRAX data to color-coded outcomes, he makes it easier for patients to visualize and understand their personal risk levels.
 
  • ICUROS & RICO: He served as the US Principal Investigator for ICUROS (International Costs and Utilities Related to Osteoporotic Fractures) and RICO (Risk Communication and Osteoporosis).
 
  • AI Integration: Current studies involve using Artificial Intelligence to identify fracture risk from routine chest X-rays, allowing for earlier intervention and better outcomes.
Distressed female athlete resting on a running track
MULTISYSTEMIC INNOVATION

Breakthroughs in Fibromyalgia and Chronic Fatigue

Dr. Silverman helped direct the first international congress on fibromyalgia and has spent years leading multidisciplinary rehab clinics at Cedars-Sinai Medical Center. His research treats these conditions as multisystemic disorders involving dysautonomia and mitochondrial health.
 
  • Cognitive Function Trial: He is currently a co-investigator on a trial studying the effects of plasmapheresis and ivIGG on cognitive functioning (brain fog) in fibromyalgia patients.
 
  • Mitochondrial & Autophagy Research: We address chronic fatigue by investigating neurotransmitter imbalances and energy production at the cellular level.
 
  • Vagal Nerve Stimulation: Dr. Silverman is working on nonpharmacologic devices designed for vagal stimulation to help regulate the autonomic nervous system.
A person in a blue shirt holding their finger, possibly suffering from osteoarthritis
THE FUTURE OF JOINT CARE

Ongoing Osteoarthritis Studies

Our research into joint health looks beyond surface-level pain management to address structural and genetic causes of inflammation.
 
  • Genetic Factors: We are currently investigating the use of genetic factors to reduce inflammation.
 
  • Stem Cell Research: Recent work has included the use of genetically modified stem cells to address cartilage loss and joint degradation.
 
  • Peptide Therapy: Exploring the use of simple peptides as a non-surgical alternative to reduce systemic inflammation.

Evidence-Based Care Rooted in Discovery

International Trustee:

As a member of the Board of Trustees for the International Osteoporosis Foundation (IOF), Dr. Silverman helps set the global standards for bone care.
 

 

Quality Standards:

He has served on task forces for the Joint Commission on Hospital Accreditation to improve secondary fracture prevention standards.
 

 

Patient-Centric Focus:

Every study, from AI diagnostics to color-coded outcome data, is designed to empower you with clearer information and better choices.
Happy family with two kids playing with kite at park
YOUR QUESTIONS ANSWERED

Frequently Asked Questions

What is Dr. Silverman’s H-index and why does it matter?

Dr. Silverman has an H-index of 55, which measures the productivity and citation impact of his 300+ publications. This score places him in the top 5% of physicians globally, ensuring that your care is guided by one of the world's leading medical researchers.


What is the OPAQ questionnaire in osteoporosis?

The OPAQ, or Osteoporosis Assessment Questionnaire, was the first tool developed to measure how osteoporosis specifically impacts a patient's quality of life. Dr. Silverman created this to ensure that bone health management focuses on the patient’s daily experience, not just their test scores.


How does Dr. Silverman use AI for bone health?

Our current research uses Artificial Intelligence to analyze routine chest X-rays. This technology helps identify potential fracture risks and bone quality issues that might otherwise be missed, allowing for a more proactive and professional approach to prevention.


What are the ICUROS and RICO studies?

ICUROS studied the global costs and impact of osteoporotic fractures, while RICO focused on using color-coded outcome data to improve risk communication. Dr. Silverman led these studies in the US to help patients better understand their health data.


Does Dr. Silverman research treatments for Long Haul COVID?

Yes, his research into chronic fatigue and fibromyalgia overlaps with Long Haul COVID. He utilizes protocols developed by major centers like Mount Sinai in New York and investigates neurotransmitter balance and mitochondrial efficiency to help restore patient energy.
PARTNER WITH A GLOBAL LEADER

Contact Us Today to Experience Research-Driven Care

Don't settle for standard care when you can be treated by a doctor at the forefront of medical discovery. Call our Beverly Hills office at 310-358-2234 to schedule your consultation.
Contact Us

Explore All Of Our Services

To provide you with the most comprehensive care, we offer specialized evaluation and management across these core clinical areas. Select a service below to learn more about our professional approach in Beverly Hills, CA.

Click on a service to learn more.

• Osteoporosis • Fibromyalgia • Chronic Fatigue & Long Haul COVID • Mast Cell Activation (MCAS) • Osteoarthritis • Lipomatosis (Dercum’s Disease)